SCHEMBL5134963

SCHEMBL5134963

CCCCn1c(CN(CCc2ccc(OCc3ccccc3)cc2)Cc2ccc3c(c2)OCO3)cnc1-c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.51
BCHE P06276 3/20 0.42
TP53 P04637 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HTR2A P28223 3/20 0.42
HTR2C P28335 3/20 0.42
HTR2B P41595 3/20 0.42
POLB P06746 2/20 0.42
PPARG P37231 1/20 0.42
PPARA Q07869 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
MAOB P27338 1/20 0.42
ADRB1 P08588 1/20 0.41
HTR1A P08908 1/20 0.41
ADRA2A P08913 1/20 0.41
DRD2 P14416 1/20 0.41
ADRA2B P18089 1/20 0.41
ADRA2C P18825 1/20 0.41
DRD1 P21728 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135671 0.94 C5AR1 (0.52) C5AR1TP53SMN1; SMN2HTR2AHTR2C
SCHEMBL4766677 0.94 C5AR1 (0.56) C5AR1TP53SMN1; SMN2HTR2AHTR2C
SCHEMBL5136131 0.92 C5AR1 (0.52) C5AR1TP53SMN1; SMN2HTR2AHTR2C
SCHEMBL5136535 0.91 C5AR1 (0.57) C5AR1TP53SMN1; SMN2HTR2AHTR2C
SCHEMBL5136897 0.90 C5AR1 (0.55) C5AR1TP53SMN1; SMN2HTR2AHTR2C
SCHEMBL5135111 0.90 C5AR1 (0.54) C5AR1TP53SMN1; SMN2HTR2AHTR2C
SCHEMBL5135700 0.89 C5AR1 (0.53) C5AR1TP53SMN1; SMN2HTR2AHTR2C
SCHEMBL5134794 0.89 C5AR1 (0.53) C5AR1TP53SMN1; SMN2HTR2AHTR2C
SCHEMBL5137845 0.89 HTR2A (0.54) C5AR1TP53SMN1; SMN2HTR2AHTR2C
SCHEMBL5136702 0.88 C5AR1 (0.51) C5AR1TP53SMN1; SMN2HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed